ConductScience.org, home

Paper39842011

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.

Ruff CT and 19 others. N Engl J Med, 2025. Cited by 94 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. Papers, record 39842011. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39842011

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
PubMed
Journal
N Engl J Med
PubMed
Year
2025
PubMed
Publication types
Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
94
iCite
Relative citation ratio, by iCite
25.57, provisional
iCite
Revised in PubMed
2026-05-18
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ruff CTChristian T
2Patel SMSiddharth Mhttps://orcid.org/0000-0002-4637-4361
3Giugliano RPRobert P
4Morrow DADavid A
5Hug BBruce
6Kuder JFJulia F
7Goodrich ELErica L
8Chen SAShih-Ann
9Goodman SGShaun G
10Joung BBoyounghttps://orcid.org/0000-0001-9036-7225
11Kiss RGRobert G
12Spinar JJindrich
13Wojakowski WWojciech
14Weitz JIJeffrey I
15Murphy SASabina A
16Wiviott SDStephen D
17Parkar SSanobar
18Bloomfield DDaniel
19Sabatine MSMarc S
20AZALEA–TIMI 71 InvestigatorsGroup

Source PubMed

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
AnticoagulantsMajor topic
Atrial FibrillationMajor topic
Factor Xa InhibitorsMajor topic
HemorrhageMajor topic
RivaroxabanMajor topic
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Administration, Oral
Double-Blind Method
Factor XI
Injections, Subcutaneous
Stroke
Incidence
Severity of Illness Index
Follow-Up Studies
Treatment Outcome

Source PubMed

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04755283Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial FibrillationResultsYes

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in40,239,081Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.https://conductscience.org/library/papers/40239081PubMed
Comment in40,239,082Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.https://conductscience.org/library/papers/40239082PubMed
Comment in40,239,083Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. Reply.https://conductscience.org/library/papers/40239083PubMed

Cited by61

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.

PMIDTitleJournalYearIn PapersSource
42,964,437Warfarin After Seven Decades: Persistent Value and the Contemporary Role of Vitamin K Antagonism.Cardiol Res2026https://conductscience.org/library/papers/42964437PubMed
42,961,609Safety, Pharmacokinetics, and Pharmacodynamics of SHR-2004, a Novel Humanized Monoclonal Antibody Targeting Factor XI, in Patients with Atrial Fibrillation: An Open-Label Phase 1b Study.Clin Pharmacokinet2026https://conductscience.org/library/papers/42961609PubMed
42,939,623Direct Oral Anticoagulants in the Cardiorenal Patient: Pharmacology, Kidney Function Estimation and Dose Selection Across the CKD Spectrum.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42939623PubMed
42,936,593Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42936593PubMed
42,936,574Measuring up: the need for new assays for factor (F)XI/FXIa inhibitor therapies.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42936574PubMed
42,936,046Perspectives: what we are learning from factor XI/factor XIa inhibitor trials.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42936046PubMed
42,923,5022026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines (Part II) on Stroke Prevention in Atrial Fibrillation.J Arrhythm2026https://conductscience.org/library/papers/42923502PubMed
42,898,680Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors.Front Immunol2026https://conductscience.org/library/papers/42898680PubMed
42,897,704Atrial fibrillation in stroke patients: facts, numbers and current challenges.Neurol Res Pract2026https://conductscience.org/library/papers/42897704PubMed
42,888,464FXI and FXII in experimental stroke and FXI in clinical stroke trials.Neurol Res Pract2026https://conductscience.org/library/papers/42888464PubMed
42,881,892Factor XI and XIa Inhibitors: A State-of-the-Art Review Across Clinical Indications.J Clin Med2026https://conductscience.org/library/papers/42881892PubMed
42,876,548Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition.Front Pharmacol2026https://conductscience.org/library/papers/42876548PubMed
42,870,289Anticoagulation-associated hemorrhage in atrial fibrillation as a marker of occult malignancy: a narrative review.Thromb J2026https://conductscience.org/library/papers/42870289PubMed
42,847,068Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm.ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/42847068PubMed
42,828,316A New Paradigm for Precision Medicine in Heatstroke: From Molecular Subtyping to Targeted Prevention and Treatment.J Inflamm Res2026https://conductscience.org/library/papers/42828316PubMed
42,795,953Coronary Artery Disease and Atrial Fibrillation in HighBleeding Risk: Indications and Optimal Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion.J Clin Med2026https://conductscience.org/library/papers/42795953PubMed
42,628,751Structural insights into the exosite-mediated activation of factor IX by factor XIa using cryogenic electron microscopy.J Thromb Haemost2026https://conductscience.org/library/papers/42628751PubMed
42,599,041Factor XI Inhibition for Ischemic Stroke Secondary Prevention: Pharmacology, Clinical Evidence, and Future Directions.J Clin Pharmacol2026https://conductscience.org/library/papers/42599041PubMed
42,590,048Anticoagulation Stewardship in the Era of Practice-Changing Evidence: A Narrative Review of Recent Trials and Their Bedside Translation.J Clin Med2026https://conductscience.org/library/papers/42590048PubMed
42,275,249Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat).Blood2026https://conductscience.org/library/papers/42275249PubMed

See all 61 cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ABELACIMABCHEMBL4650369Results1https://conductscience.org/library/drugs/CHEMBL4650369

Source ChEMBL

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39842011

GET https://conductscience.org/api/papers/v1/39842011/cited_by?page=2